Trials / Terminated
TerminatedNCT01033149
N-acetylcysteine in the Treatment of Bulimia Nervosa
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Lindner Center of HOPE · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of N-acetylcysteine (NAC) in the treatment on bulimia nervosa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-acetylcysteine | N-acetylcysteine, flexible dose 1200-2400mg/day |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2009-12-16
- Last updated
- 2014-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01033149. Inclusion in this directory is not an endorsement.